{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:21:36Z","timestamp":1774329696837,"version":"3.50.1"},"reference-count":38,"publisher":"The Russian Academy of Sciences","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molekul\u00e2rna\u00e2 biologi\u00e2"],"abstract":"<jats:p>Alzheimer\u2019s disease (AD) is the most common proteinopathy, which is accompanied by a steady decrease in the patient\u2019s cognitive functions with simultaneous accumulation of extracellular aggregates of amyloid \u03b2 (A\u03b2) \u2013 amyloid plaques in the brain tissues and associated with neuroinflammation and neurodegeneration. Unlike humans and all other mammals, rats and mice have three amino acid substitutions in A\u03b2 and do not reproduce the Alzheimer\u2019s pathology. However, the appearance of amyloid plaques is observed in the brains of transgenic mice with the overexpression of human A\u03b2, which makes it possible to widely use these transgenic animals in biomedicine for the manifestation of AD. Transgenic mouse line APPswe\/PS1dE9 is a widely used animal model for the study of the molecular mechanisms of AD. In this paper we provide a detailed description of the APPswe\/PS1dE9\/Blg subline of animals obtained by crossing APPswe\/PS1dE9 mice on a CH3 genetic background with C57Bl6\/Chg animals. We have shown no difference in parameters of offspring\u2019s survival and fertility of this line compared to wild-type control animals. Histological analysis of the brain of APPswe\/PS1dE9\/Blg line confirmed the main neuromorphological feature of AD with the progression in number and size of amyloid plaques during aging. Thus, APPswe\/PS1dE9\/Blg line is a convenient model in the search for therapeutic strategies for AD.<\/jats:p>","DOI":"10.31857\/s0026898423010081","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T06:54:29Z","timestamp":1713509669000},"page":"85-94","source":"Crossref","is-referenced-by-count":3,"title":["APPswe\/PS1dE9\/Blg Transgenic Mouse Line for Modeling Cerebral Amyloid Angiopathy in Alzheimer\u2019s Disease"],"prefix":"10.31857","volume":"57","author":[{"given":"E. A.","family":"Lysikova","sequence":"first","affiliation":[{"name":"Institute of Physiologically Active Compounds, Russian Academy of Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. V.","family":"Kuzubova","sequence":"additional","affiliation":[{"name":"Belgorod State University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. I.","family":"Radchenko","sequence":"additional","affiliation":[{"name":"Belgorod State University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. A.","family":"Patrakhanov","sequence":"additional","affiliation":[{"name":"Belgorod State University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. D.","family":"Chaprov","sequence":"additional","affiliation":[{"name":"Institute of Physiologically Active Compounds, Russian Academy of Sciences"},{"name":"Belgorod State University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. V.","family":"Korokin","sequence":"additional","affiliation":[{"name":"Belgorod State University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. V.","family":"Deykin","sequence":"additional","affiliation":[{"name":"Belgorod State University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. S.","family":"Gudyrev","sequence":"additional","affiliation":[{"name":"Belgorod State University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. V.","family":"Pokrovskii","sequence":"additional","affiliation":[{"name":"Belgorod State University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17106","published-online":{"date-parts":[[2023,1,1]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Konttinen H., Cabral-da-Silva M.E.C., Ohtonen S., Wojciechowski S., Shakirzyanova A., Caligola S., Giugno R., Ishchenko Y., Hernandez D., Fazaludeen M.F., Eamen S., Budia M.G., Fagerlund I., Scoyni F., Korhonen P., Huber N., Haapasalo A., Hewitt A.W., Vickers J., Smith G.C., Oksanen M., Graff C., Kanninen K.M., Lehtonen S., Propson N., Schwartz M.P., Pebay A., Koistinaho J., Ooi L., Malm T. (2019) PSEN1DeltaE9, APPswe, and APOE4 confer disparate phenotypes in human iPSC-derived microglia. Stem. Cell Rep. 13, 669\u2013683.","DOI":"10.1016\/j.stemcr.2019.08.004"},{"key":"ref2","unstructured":"\u0428\u0435\u043b\u043a\u043e\u0432\u043d\u0438\u043a\u043e\u0432\u0430 \u0422.\u0410., \u041a\u0443\u043b\u0438\u043a\u043e\u0432\u0430 \u0410.\u0410., \u0426\u0432\u0435\u0442\u043a\u043e\u0432 \u0424.\u041e., Peters O., \u0411\u0430\u0447\u0443\u0440\u0438\u043d \u0421.\u041e., \u0411\u0443\u0445\u043c\u0430\u043d \u0412.\u041b., \u041d\u0438\u043d\u043a\u0438\u043d\u0430 \u041d.\u041d. (2012) \u041f\u0440\u043e\u0442\u0435\u0438\u043d\u043e\u043f\u0430\u0442\u0438\u0438 \u2013 \u0444\u043e\u0440\u043c\u044b \u043d\u0435\u0439\u0440\u043e\u0434\u0435\u0433\u0435\u043d\u0435\u0440\u0430\u0442\u0438\u0432\u043d\u044b\u0445 \u0437\u0430\u0431\u043e\u043b\u0435\u0432\u0430\u043d\u0438\u0439, \u0432 \u043e\u0441\u043d\u043e\u0432\u0435 \u043a\u043e\u0442\u043e\u0440\u044b\u0445 \u043b\u0435\u0436\u0438\u0442 \u043f\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u0430\u0433\u0440\u0435\u0433\u0430\u0446\u0438\u044f \u0431\u0435\u043b\u043a\u043e\u0432. \u041c\u043e\u043b\u0435\u043a\u0443\u043b\u044f\u0440. \u0431\u0438\u043e\u043b\u043e\u0433\u0438\u044f. 46, 402\u2013415."},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Masters C.L., Bateman R., Blennow K., Rowe C.C., Sperling R.A., Cummings J.L. (2015) Alzheimer\u2019s disease. Nat. Rev. Dis. Primers. 1, 15056.","DOI":"10.1038\/nrdp.2015.56"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Kozin S.A., Cheglakov I.B., Ovsepyan A.A., Telegin G.B., Tsvetkov P.O., Lisitsa A.V., Makarov A.A. (2013) Peripherally applied synthetic peptide isoAsp7-Abeta(1-42) triggers cerebral beta-amyloidosis. Neurotoxicity Res. 24, 370\u2013376.","DOI":"10.1007\/s12640-013-9399-y"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Evin G., Li Q.X. (2012) Platelets and Alzheimer\u2019s disease: potential of APP as a biomarker. W. J. Psychiatry. 2, 102\u2013113.","DOI":"10.5498\/wjp.v2.i6.102"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Vetrivel K.S., Thinakaran G. (2006) Amyloidogenic processing of beta-amyloid precursor protein in intracellular compartments. Neurology. 66, S69\u201373.","DOI":"10.1212\/01.wnl.0000192107.17175.39"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"De Strooper B., Annaert W. (2010) Novel research horizons for presenilins and gamma-secretases in cell biology and disease. Annu. Rev. Cell. Dev. Biol. 26, 235\u2013260.","DOI":"10.1146\/annurev-cellbio-100109-104117"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Manczak M., Kandimalla R., Yin X., Reddy P.H. (2018) Hippocampal mutant APP and amyloid beta-induced cognitive decline, dendritic spine loss, defective autophagy, mitophagy and mitochondrial abnormalities in a mouse model of Alzheimer\u2019s disease. Hum. Mol. Genet. 27, 1332\u20131342.","DOI":"10.1093\/hmg\/ddy042"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Pan J.X., Sun D., Lee D., Xiong L., Ren X., Guo H.H., Yao L.L., Lu Y., Jung C., Xiong W.C. (2021) Osteoblastic Swedish mutant APP expedites brain deficits by inducing endoplasmic reticulum stress-driven senescence. Commun. Biol. 4, 1326.","DOI":"10.1038\/s42003-021-02843-2"},{"key":"ref10","unstructured":"\u0422\u0430\u0442\u0430\u0440\u043d\u0438\u043a\u043e\u0432\u0430 \u041e.\u0413., \u041e\u0440\u043b\u043e\u0432 \u041c.\u0410., \u0411\u043e\u0431\u043a\u043e\u0432\u0430 \u041d.\u0412. (2015) \u0411\u0435\u0442\u0430-\u0430\u043c\u0438\u043b\u043e\u0438\u0434 \u0438 \u0442\u0430\u0443-\u0431\u0435\u043b\u043e\u043a: \u0441\u0442\u0440\u0443\u043a\u0442\u0443\u0440\u0430, \u0432\u0437\u0430\u0438\u043c\u043e\u0434\u0435\u0439\u0441\u0442\u0432\u0438\u0435 \u0438 \u043f\u0440\u0438\u043e\u043d\u043e\u043f\u043e\u0434\u043e\u0431\u043d\u044b\u0435 \u0441\u0432\u043e\u0439\u0441\u0442\u0432\u0430. \u0423\u0441\u043f\u0435\u0445\u0438 \u0431\u0438\u043e\u043b. \u0445\u0438\u043c\u0438\u0438. 55, 351\u2013390."},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Armstrong R.A. (2019) Risk factors for Alzheimer\u2019s disease. Folia Neuropathol. 57, 87\u2013105.","DOI":"10.5114\/fn.2019.85929"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., Copeland N.G., Lee M.K., Younkin L.H., Wagner S.L., Younkin S.G., Borchelt D.R. (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 13, 159\u2013170.","DOI":"10.1093\/hmg\/ddh019"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Sasaguri H., Hashimoto S., Watamura N., Sato K., Takamura R., Nagata K., Tsubuki S., Ohshima T., Yoshiki A., Sato K., Kumita W., Sasaki E., Kitazume S., Nilsson P., Winblad B., Saito T., Iwata N., Saido T.C. (2022) Recent advances in the modeling of Alzheimer\u2019s disease. Front. Neurosci. 16, 807473.","DOI":"10.3389\/fnins.2022.807473"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Games D., Adams D., Alessandrini R., Barbour R., Borthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., Guido T., Hagopian S., Johnson-Wood K., Khan K., Lee M., Leibowitz P., Lieberburg I., Little S., Masliah E., McConlogue L., Montoya-Zavala M., Mucke L., Paganini L., Penniman E., Power M., Schenk D., Seubert P., Snyder B., Soriano F., Tan H., Vitale J., Wadsworth S., Wolozin B., Zhao J. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 373, 523\u2013527.","DOI":"10.1038\/373523a0"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Kuo Y.M., Beach T.G., Sue L.I., Scott S., Layne K.J., Kokjohn T.A., Kalback W.M., Luehrs D.C., Vishnivetskaya T.A., Abramowski D., Sturchler-Pierrat C., Staufenbiel M., Weller R.O., Roher A.E. (2001) The evolution of A beta peptide burden in the APP23 transgenic mice: implications for A beta deposition in Alzheimer disease. Mol. Med. 7, 609\u2013618.","DOI":"10.1007\/BF03401867"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 274, 99\u2013102.","DOI":"10.1126\/science.274.5284.99"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Davis J., Xu F., Deane R., Romanov G., Previti M.L., Zeigler K., Zlokovic B.V., Van Nostrand W.E. (2004) Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch\/Iowa mutant form of amyloid beta-protein precursor. J. Biol. Chem. 279, 20296\u201320306.","DOI":"10.1074\/jbc.M312946200"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. (2003) Triple-transgenic model of Alzheimer\u2019s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 39, 409\u2013421.","DOI":"10.1016\/S0896-6273(03)00434-3"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Jankowsky J.L., Slunt H.H., Ratovitski T., Jenkins N.A., Copeland N.G., Borchelt D.R. (2001) Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Engin. 17, 157\u2013165.","DOI":"10.1016\/S1389-0344(01)00067-3"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., Berry R., Vassar R. (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer\u2019s disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129\u201310140.","DOI":"10.1523\/JNEUROSCI.1202-06.2006"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. (2000) High-level neuronal expression of abeta 1\u201342 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050\u20134058.","DOI":"10.1523\/JNEUROSCI.20-11-04050.2000"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Radde R., Bolmont T., Kaeser S.A., Coomaraswamy J., Lindau D., Stoltze L., Calhoun M.E., Jaggi F., Wolburg H., Gengler S., Haass C., Ghetti B., Czech C., Holscher C., Mathews P.M., Jucker M. (2006) Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 7, 940\u2013946.","DOI":"10.1038\/sj.embor.7400784"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O\u2019Campo K., Hardy J., Prada C.M., Eckman C., Younkin S., Hsiao K., Duff K. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4, 97\u2013100.","DOI":"10.1038\/nm0198-097"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Kurt M.A., Davies D.C., Kidd M., Duff K., Rolph S.C., Jennings K.H., Howlett D.R. (2001) Neurodegenerative changes associated with beta-amyloid deposition in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Exp. Neurol. 171, 59\u201371.","DOI":"10.1006\/exnr.2001.7717"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"McGowan E., Sanders S., Iwatsubo T., Takeuchi A., Saido T., Zehr C., Yu X., Uljon S., Wang R., Mann D., Dickson D., Duff K. (1999) Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol. Dis. 6, 231\u2013244.","DOI":"10.1006\/nbdi.1999.0243"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Toda T., Noda Y., Ito G., Maeda M., Shimizu T. (2011) Presenilin-2 mutation causes early amyloid accumulation and memory impairment in a transgenic mouse model of Alzheimer\u2019s disease. J. Biomed. Biotechnol. 2011, 617974.","DOI":"10.1155\/2011\/617974"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Rockenstein E., Mallory M., Mante M., Sisk A., Masliaha E. (2001) Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42). J. Neurosci. Res. 66, 573\u2013582.","DOI":"10.1002\/jnr.1247"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Platt B., Drever B., Koss D., Stoppelkamp S., Jyoti A., Plano A., Utan A., Merrick G., Ryan D., Melis V., Wan H., Mingarelli M., Porcu E., Scrocchi L., Welch A., Riedel G. (2011) Abnormal cognition, sleep, EEG and brain metabolism in a novel knock-in Alzheimer mouse, PLB1. PloS One. 6, e27068.","DOI":"10.1371\/journal.pone.0027068"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Saito T., Matsuba Y., Mihira N., Takano J., Nilsson P., Itohara S., Iwata N., Saido T.C. (2014) Single App knock-in mouse models of Alzheimer\u2019s disease. Nat. Neurosci. 17, 661\u2013663.","DOI":"10.1038\/nn.3697"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Sato K., Watamura N., Fujioka R., Mihira N., Sekiguchi M., Nagata K., Ohshima T., Saito T., Saido T.C., Sasaguri H. (2021) A third-generation mouse model of Alzheimer\u2019s disease shows early and increased cored plaque pathology composed of wild-type human amyloid beta peptide. J. Biol. Chem. 297, 101004.","DOI":"10.1016\/j.jbc.2021.101004"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Jankowsky J.L., Xu G., Fromholt D., Gonzales V., Borchelt D.R. (2003) Environmental enrichment exacerbates amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J. Neuropathol. Exp. Neurol. 62, 1220\u20131227.","DOI":"10.1093\/jnen\/62.12.1220"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Lysikova E.A., Kukharsky M.S., Chaprov K.D., Vasilieva N.A., Roman A.Y., Ovchinnikov R.K., Deykin A.V., Ninkina N., Buchman V.L. (2019) Behavioural impairments in mice of a novel FUS transgenic line recapitulate features of frontotemporal lobar degeneration. Genes Brain Behavior. 18, e12607.","DOI":"10.1111\/gbb.12607"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"D'Angelo C., Costantini E., Salvador N., Marchioni M., Di Nicola M., Greig N.H., Reale M. (2021) nAChRs gene expression and neuroinflammation in APPswe\/PS1dE9 transgenic mouse. Sci. Rep. 11, 9711.","DOI":"10.1038\/s41598-021-89139-x"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Kuhla A., Ruhlmann C., Lindner T., Polei S., Hadlich S., Krause B.J., Vollmar B., Teipel S.J. (2017) APPswe\/PS1dE9 mice with cortical amyloid pathology show a reduced NAA\/Cr ratio without apparent brain atrophy: a MRS and MRI study. Neuroimage Clin. 15, 581\u2013586.","DOI":"10.1016\/j.nicl.2017.06.009"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Pezzini A., Del Zotto E., Volonghi I., Giossi A., Costa P., Padovani A. (2009) Cerebral amyloid angiopathy: a common cause of cerebral hemorrhage. Curr. Med. Chem. 16, 2498\u20132513.","DOI":"10.2174\/092986709788682047"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Tsvetkov P.O., Cheglakov I.B., Ovsepyan A.A., Mediannikov O.Y., Morozov A.O., Telegin G.B., Kozin S.A. (2015) Peripherally applied synthetic tetrapeptides HAEE and RADD slow down the development of cerebral beta-amyloidosis in AbetaPP\/PS1 transgenic mice. J. Alzheimer\u2019s Dis. 46, 849\u2013853.","DOI":"10.3233\/JAD-150031"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Kozin S.A., Barykin E.P., Telegin G.B., Chernov A.S., Adzhubei A.A., Radko S.P., Mitkevich V.A., Makarov A.A. (2018) Intravenously injected amyloid-beta peptide with isomerized Asp7 and phosphorylated Ser8 residues inhibits cerebral beta-amyloidosis in AbetaPP\/PS1 transgenic mice model of Alzheimer\u2019s disease. Front. Neurosci. 12, 518.","DOI":"10.3389\/fnins.2018.00518"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Barykin E.P., Petrushanko I.Y., Kozin S.A., Telegin G.B., Chernov A.S., Lopina O.D., Radko S.P., Mitkevich V.A., Makarov A.A. (2018) Phosphorylation of the amyloid-beta peptide inhibits zinc-dependent aggregation, prevents Na,K-ATPase inhibition, and reduces cerebral plaque deposition. Front. Mol. Neurosci. 11, 302.","DOI":"10.3389\/fnmol.2018.00302"}],"container-title":["\u041c\u043e\u043b\u0435\u043a\u0443\u043b\u044f\u0440\u043d\u0430\u044f \u0431\u0438\u043e\u043b\u043e\u0433\u0438\u044f"],"original-title":[],"link":[{"URL":"https:\/\/journals.rcsi.science\/0026-8984\/article\/viewFile\/138601\/116538","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.rcsi.science\/0026-8984\/article\/viewFile\/138601\/116538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T22:04:19Z","timestamp":1718229859000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.rcsi.science\/0026-8984\/article\/view\/138601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,1]]}},"URL":"https:\/\/doi.org\/10.31857\/s0026898423010081","relation":{},"ISSN":["0026-8984"],"issn-type":[{"value":"0026-8984","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,1]]}}}